Media
Media Inquiries: media@alzpath.bio
ALZpath Press Releases
ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024
October 30th, 2024
New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis
July 29th, 2024
ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease
July 15th, 2024
ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer
July 9th, 2024
ALZpath Partners with Roche to Provide pTau217 Antibody for Alzheimer's Diagnostic Blood Test
June 10th, 2024
Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research
February 29th, 2024
New Study in JAMA Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test
JANUARY 22, 2024
ALZpath Announces Partnership with ADDF for Clinical Alzheimer's Diagnostic Launch
JULY 18, 2023
ALZpath News
ALZforum Highlights ALZpath's pTau217 Test in Round Robin
November 30, 2023
“p-tau 217 tests outdid the rest of the flock” reported ALZforum in an article last week, featuring the ALZpath assay in the Alzheimer’s Disease Biomarker Round Robin lead by Dr. Nicholas Ashton. We are immensely proud to collaborate with Dr. Ashton and contribute to his groundbreaking research that sets new standards in Alzheimer’s biomarker assay evaluation.
Invaluable Study Provides Compelling Evidence for the Clinical Use of ALZpath Assay
SEPTEMBER 26, 2023
Dr. Therriault and their dedicated team have launched a preprint in The Lancet reporting on their essential study delving into the performance of pTau217 assays. The findings from this research strongly support the diagnostic excellence of the ALZpath pTau217 assay for identifying Alzheimer’s disease, and its robust association with amyloid-PET and tau-PET – the current clinical standards for Alzheimer’s pathology diagnosis.
Pivotal Study Reports Biological and Analytical Variation for pTau217
AUGUST 13, 2023
Dr. Wagner Brum and their exceptional team have illuminated the biological variation in leading blood-based biomarkers for Alzheimer’s disease, and found pTau217 has low individual biological variation compared to pTau181. We are honored that this study utilized our ALZpath pTau217 assay to determine the biological variation in pTau217.
ALZpath Announces Partnership with ADDF for Clinical Alzheimer's Diagnostic Launch
JULY 18, 2023
ALZpath is proud to share that we have received funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate clinical availability of our blood based Alzheimer’s diagnostic test. This investment comes at a pivotal time as the first approval of a disease modifying therapy ushering in a new era in Alzheimer’s clinical care.
ALZpath to Present at AAIC Meeting
JULY 16-20, 2023
We are proud to share that we will join prominent researchers evaluating biomarkers for Alzheimer’s Disease that have utilized our cutting-edge pTau217 assay at the Alzheimer’s Association International Conference (AAIC) in Amsterdam. Follow the link below for a list of presentations of their important findings.
Breakthrough Study Reveals Diagnostic Power of ALZpath pTau217 Assay
JULY 12, 2023
The ALZpath pTau217 assay has been featured in a crucial evaluation of biomarkers of Alzheimer’s disease pathology. Dr. Nicholas Ashton and team demonstrated our ALZpath pTau217 assay can accurately identify and longitudinally monitor Alzheimer’s disease pathology, including in preclinical stages.
ALZpath Featured at AAN Meeting
APRIL 24, 2023
A recent study presented at the annual American Academy of Neurology (AAN) meeting found that the ALZpath pTau217 assay detected elevated pTau217 in Alzheimers Disease with the greatest fold difference for any assay evaluated. Further, the ALZpath pTau217 assay identified Alzheimer’s disease in mild cases, as well as moderate and severe.
Clinical Trials on Alzheimer Disease (CTAD)
DECEMBER 27, 2022
Plasma pTau217 has emerged as a promising biomarker for amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. Studies indicate it can accurately detect positive individuals and predict future decline. Blood draws for pTau217 may soon replace PET scans in clinical trials.
ALZpath Announces Novel Scalable Assay for pTau217
NOVEMBER 11, 2022
“ALZpath, Inc.”, an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated an Scalable Assay for Detection of Phosphorylated Tau 217 in Blood.
